Updated on 11 August 2014
INVOKAMET is indicated for managing type 2 diabetes
Singapore: US Food and Drug Administration (FDA) has approved Janssen Pharmaceuticals' INVOKAMET, a fixed-dose therapy combining canagliflozin
and metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes.
"INVOKAMET combines, in one tablet, two complementary therapeutic approaches proven effective for managing type 2 diabetes," said Mr Richard Aguilar, MD, Medical Director of Diabetes Nation.
"Canagliflozin works with the kidney to promote the loss of glucose in the urine, whereas metformin decreases the production of glucose in the liver and improves the body's response to insulin."
INVOKAMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled by treatment that includes either canagliflozin or metformin, or who are already being treated with both canagliflozin and metformin as separate medications.
"As with INVOKANA, INVOKAMET provides adults with type 2 diabetes an oral therapy that lowers blood sugar and is also associated with reductions in body weight and systolic blood pressure," said Dr Jimmy Ren, therapeutic area lead, metabolics, Medical Affairs, Janssen Pharmaceuticals.